Objective: It has been speculated that amyotrophic lateral sclerosis (ALS) is characterized by a premanifest period during which neurodegeneration precedes the appearance of clinical manifestations. Magnetic resonance spectroscopy (MRS) was used to measure ratios of neurometabolites in the cervical spine of asymptomatic individuals with a mutation in the SOD1 gene (SOD1ϩ) and compare their neurometabolic ratios to patients with ALS and healthy controls.
It has been speculated that amyotrophic lateral sclerosis (ALS) is characterized by a premanifest period during which neuronal degeneration precedes the appearance of clinical symptoms. Some evidence of this premanifest period has been derived from the superoxide dismutase (SOD1) mouse model of ALS in which there is a decline in the estimated motor unit number in advance of the appearance of symptoms. 1 Limited data from a number of healthy individuals at risk for ALS by virtue of their carrying a mutation in the SOD1 gene (SOD1ϩ) suggest a decline in motor unit numbers several months in advance of the appearance of symptoms. 2 Similarly, limited threshold tracking transcranial magnetic stimulation data from 3 presymptomatic SOD1ϩ individuals suggests an increase in cortical excitability within 3 months prior to the onset of symptoms. 3 Finally, a single prior study of 8 presymptomatic SOD1 mutation carriers reported decreased fractional anisotropy, increased tensor trace, and increased radial diffusivity in the posterior limb of the internal capsule. 4 Magnetic resonance spectroscopy (MRS) is a noninvasive method for in vivo measurement of tissue metabolites that has been used to study neurometabolites in ALS, [5] [6] [7] [8] [9] [10] but there have been no prior studies of MRS in a presymptomatic population at risk for developing ALS. A number of studies have demonstrated a reduction in N-acetylaspartate (NAA), a marker of neuronal loss, in patients with ALS compared to controls expressed as absolute concentrations, 11, 12 or as ratios of other metabolites like choline (Cho) and creatine (Cr) 10, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] in the primary motor cortex, 13, 17, 19, 23, 25, 26 centrum semiovale, internal capsule, corticospinal tract, cervical spine, 10,12,23 medulla, 5 and brainstem. Whether similar findings might be evident in people at risk for developing ALS, however, remains an unanswered question.
Here we present the results of an MRS study of presymptomatic SOD1ϩ individuals, contrasting the findings to those observed in patients with established ALS as well as age-matched healthy controls. The objective of our study was to determine whether there are changes in metabolite ratios in asymptomatic SOD1ϩ subjects in advance of the onset of disease. Magnetic resonance-detectable changes to metabolite concentration could potentially serve as a surrogate marker for disease progression.
METHODS Participants. This study was approved by the Emory University Institutional Review Board. All participants provided written informed consent.
Presymptomatic SOD1ϩ individuals were participants in the Pre-familial ALS (Pre-fALS) study, an ongoing prospective observational study of people who are at risk for developing familial ALS because they harbor a mutation in an ALS susceptibility gene. Participants for this study were recruited from among healthy relatives of patients with fALS due to mutations in known susceptibility genes (e.g., SOD1, TDP43, FUS). Study subjects undergo presymptomatic testing with the option of whether or not to learn the results of genetic tests. Those who elect to learn the results of genetic testing undergo both pre-test and post-test genetic counseling. Pre-fALS was initiated in 2007, and currently about 40 subjects have been enrolled in longitudinal follow-up. Pre-fALS participants are evaluated using multiple investigative modalities in an effort to identify presymptomatic evidence for disease. Included among these investigative modalities is MRS of the cervical spinal cord. All participants in Pre-fALS lack clinical symptoms and signs of upper and lower motor neuron dysfunction, and have no electrophysiologic abnormalities evident on routine nerve conduction studies and EMG, performed within 24 hours of the MRI. Participants in Pre-fALS are characterized as "presymptomatic" because: 1) ALS, as with other neurodegenerative diseases (Alzheimer disease, Parkinson disease, Huntington disease), is characterized by a presymptomatic phase of disease and 2) because those who harbor a mutation in the SOD1 gene are at an extremely high lifetime risk of developing ALS.
Cross-sectional data from Pre-fALS subjects were compared to subjects clinically diagnosed with ALS and age-matched healthy control subjects. Data from 14 patients with ALS and 16 healthy controls included in this manuscript have previously been reported 10 but are presented here again (together with data from additional patients with ALS and healthy controls) for the purpose of comparison. Participant data were collected between November 2007 and March 2010. The study size represented all available data as of March 2010. As described previously, 10 the subjects with ALS were recruited from the Emory University EMG laboratory, an ongoing clinical trial of arimoclomol in SOD1ϩ familial ALS as well as people with ALS who are registered with the Muscular Dystrophy Association. The healthy controls were recruited from several sources including spouses and other relatives of patients with ALS and a registry of healthy subjects maintained by one of the investigators (M.B.) as part of a prior study. After clinical examination, the revised ALS functional rating scale (ALSFRS-R) 27 was administered in all patients with ALS, and forced vital capacity (FVC) was measured in all subjects.
Imaging and MRS data processing. 1 H-MRS and data
acquisition was performed on all subjects as described in detail previously. 10 The participants were imaged on a 3-T whole-body system (TIM Trio, Siemens Medical Solutions, Malvern, PA) with head, neck, and spine matrix coils. A rectangular voxel (8 ϫ 5 ϫ 35 mm 3 ) was placed along the main axis of the cord (figure 1) for MRS using point-resolved spectroscopy sequence after acquisition of localizers and shimming, with repetition time/echo time ϭ 2,000/35 msec. Spectra were collected without (4 averages) and with water suppression (256 averages) using a chemical shift selective water suppression pulse. The total MRS acquisition time was approximately 12 minutes. The MRS data were fit with the LC model 28 using LCModel version 6.1-A (S.W. if the SD of the error was greater than 25%. Differences in age and metabolite ratios between patients with ALS, SOD1ϩ subjects, and controls were assessed with a 2-tailed Wilcoxon rank sum test. Multiple comparisons were addressed by controlling the false discovery rate procedure 29 at 5%, which is the expected proportion of falsely rejected null hypothesis. All statistical analyses were performed with the R statistical environment (www.r-project.org). NAA/Cr and NAA/Myo ratios are reduced in presymptomatic SOD1ϩ subjects (39.7%, p ϭ 0.001 and 18.0%, p ϭ 0.02) and patients with ALS (41.2%, p Ͻ 0.001 and 24.0%, p ϭ 0.01) compared to controls (figure 2). The Myo/Cr ratio is slightly reduced (10.3%, p ϭ 0.02) in presymptomatic SOD1ϩ subjects compared to controls, but there is no difference in this ratio between patients with ALS and controls. By contrast, NAA/Cho is reduced in patients with ALS (24.0%, p ϭ 0.002), but not in presymptomatic SOD1ϩ subjects compared to controls. After controlling the false discovery rate at 5%, our comparisons remain statistically significant.
RESULTS
The 3 comparison groups were not well balanced by sex. To determine if sex is a predictor of metabolite ratios, we performed an additional analysis among the healthy controls. For each metabolite ratio, we performed a 2-sided Wilcoxon rank sum test to determine if the metabolite ratios are different be- In general, the profile of metabolic changes in the presymptomatic SOD1ϩ group more closely resembles that found in patients with ALS than that observed in the control population. A scatterplot of NAA/Cr vs Myo/Cr (figure 3) shows a clustering pattern among the 3 subject groups. Clusters form around the patients with ALS (red) and around the healthy controls (blue). A majority of the Pre-fALS subjects (orange) tend to cluster near the patients with ALS, although a minority fall among the healthy controls. DISCUSSION There is increasing recognition that the disease process begins prior to the appearance of clinical symptoms and signs in many neurodegenerative diseases, including Parkinson disease, 30 Huntington disease, 31 and Alzheimer disease. 32 It is similarly believed that the neurodegenerative process in ALS may begin prior to the onset of symptoms, but there are relatively little human data to support this hypothesis. [2] [3] [4] An important reason for the paucity of human data is the practical difficulty of studying people at risk for ALS prior to the onset of symptoms. Pre-fALS is a prospective observational study of asymptomatic individuals from familial ALS pedigrees who harbor a mutation in an ALS susceptibility gene and are at high risk for developing ALS. This is the only known population that can realistically be studied prior to symptom onset.
In this article, we report the first MRS study of presymptomatic people who harbor a mutation in the SOD1 gene. We show that changes in neurometabolite ratios in the cervical spinal cord are evident in asymptomatic SOD1ϩ people in advance of the onset of symptoms and clinical or electromyographic signs of the disease. These changes primarily reflect a reduction in ratios of NAA to Cr and NAA to Myo. The profile of metabolite ratio changes in this population resembles that observed in patients with clinically apparent ALS, suggesting that the changes in metabolite ratios appear early in the course of the disease process. Of interest, similar observations have been made using transcranial magnetic stimulation to assess cortical excitability. Short-interval cortical inhibition is reduced together with an increase in intracortical facilitation in patients with established ALS as well as in 3 presymptomatic SOD1ϩ individuals who progressed to manifest disease within 3 months, but not in 14 asymptomatic SOD1ϩ individuals who did not develop symptoms or signs of disease during follow-up. 3 A relevant difference between these electrophysiologic findings and our spectroscopic study is that our data are cross-sectional. As such, it is unclear when each presymptomatic individual will develop symptoms of ALS. It is likely that the population is heterogeneous in this regard, with some likely to develop disease earlier than others. Importantly, we have observed group differences between the presymptomatic SOD1ϩ population and the healthy controls despite this heterogeneity. Notwithstanding these group differences, there is also significant overlap between the groups such that MRS findings in the cervical cord of individual subjects cannot readily be used to predict, for example, whether a particular individual is presymptomatic or a healthy control.
Prior studies of MRS in ALS have not consistently shown a correlation between spectroscopic markers and clinical measures of disease progression. Some investigators have noted that reductions in NAA are only present, or at least more prominent, among subjects with more severe upper motor neuron involvement, 14, 15, 17, 21, 26 or more prominent among those with El Escorial definite/probable compared to those with possible/suspected ALS, 33 while others have suggested a correlation between spectroscopic findings and clinical metrics such as the Norris functional rating scale 11 and finger tapping speeds. 23 We have previously found that changes in metabolite ratios in the cervical spinal cord of pa- tients with ALS have weak or no correlation with cross-sectional measures of disease severity such as ALSFRS-R and FVC. 10 One possible explanation for this poor correlation is that spectroscopy permits detection of presymptomatic or subclinical manifestations of the disease. An alternative (but not mutually exclusive) explanation is that the spectroscopic findings we have observed are a manifestation of mutant SOD1 gene expression and reflect a stable rather than a dynamic state. Our finding of MRS changes in SOD1ϩ subjects prior to the onset of clinical symptoms provides support for these hypotheses as well as motivation for a longitudinal MRS study in the presymptomatic SOD1ϩ population, which is currently under way as part of Pre-fALS. The next step is to unravel the temporal course of these changes in metabolite ratios in this population in order to determine whether their metabolite ratios change over time. Following SOD1ϩ people until the onset of disease will help to determine if MRS findings change over time in advance of the appearance of manifest disease and whether it might be possible to impact these changes with some form of preventative therapy. Since we currently have no ability to identify individuals at risk for developing sporadic ALS, there is limited potential to generalize our findings to people with sporadic ALS.
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